Literature DB >> 35949567

Inhaled nitric oxide for ECPELLA management in fulminant myocarditis complicated with severe right ventricular dysfunction: A case report.

Takumi Oki1, Yuki Ikeda1, Shunsuke Ishii1, Junya Ako1.   

Abstract

Combination therapy with venoarterial extracorporeal membrane oxygenation (VA-ECMO) and Impella (ECPELLA) has been known to be a favorable strategy of mechanical circulation support for patients with fatal cardiogenic shock. However, the practical strategy for weaning ECPELLA in patients with right ventricular (RV) dysfunction remains unclear. We describe a case of a 63-year-old male with fulminant myocarditis presenting with cardiogenic shock who required ECPELLA to improve hemodynamics. Because of persistent severe RV dysfunction despite the introduction of intravenous dobutamine and milrinone, VA-ECMO could not be weaned. Inhaled nitric oxide (iNO) was introduced at 20 ppm to reduce RV afterload, resulting in increased cardiac output (from 1.6 to 5.5 L/min) and ameliorated RV performance (the pulmonary artery pulsatility index was from 0.47 to 1.11). Subsequently, VA-ECMO could be weaned. iNO, a selective pulmonary vasodilator, reduces pulmonary vascular resistance, resulting in reduced RV afterload. This is the first case of iNO usage for the management of cardiogenic shock supported by ECPELLA. iNO could be a favorable strategy in ECPELLA patients with refractory RV dysfunction for weaning VA-ECMO through bridging to recovery. Learning objective: The practical strategy for weaning venoarterial extracorporeal membrane oxygenation and Impella (ECPELLA) in patients with concomitant right ventricular dysfunction remains unclear. Inhaled nitric oxygen is a novel weaning strategy for patients with biventricular dysfunction supported by ECPELLA. If the response of inhaled nitric oxygen was insufficient under ECPELLA support, implantable ventricular assist devices or transplantation should be considered.
© 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. All rights reserved.

Entities:  

Keywords:  Case report; Fulminant myocarditis; Impella; Inhaled nitric oxide; Venoarterial extracorporeal membrane oxygenation

Year:  2022        PMID: 35949567      PMCID: PMC9352424          DOI: 10.1016/j.jccase.2022.03.013

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  10 in total

1.  Clinical indication for use and outcomes after inhaled nitric oxide therapy.

Authors:  Isaac George; Steve Xydas; Veli K Topkara; Corrina Ferdinando; Eileen C Barnwell; Larissa Gableman; Robert N Sladen; Yoshifumi Naka; Mehmet C Oz
Journal:  Ann Thorac Surg       Date:  2006-12       Impact factor: 4.330

2.  Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance.

Authors:  J M Hare; S K Shernan; S C Body; E Graydon; W S Colucci; G S Couper
Journal:  Circulation       Date:  1997-05-06       Impact factor: 29.690

3.  Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension.

Authors:  M Argenziano; A F Choudhri; N Moazami; E A Rose; C R Smith; H R Levin; A J Smerling; M C Oz
Journal:  Ann Thorac Surg       Date:  1998-02       Impact factor: 4.330

4.  Concomitant implantation of Impella® on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock.

Authors:  Federico Pappalardo; Christian Schulte; Marina Pieri; Benedikt Schrage; Rachele Contri; Gerold Soeffker; Teresa Greco; Rosalba Lembo; Kai Müllerleile; Antonio Colombo; Karsten Sydow; Michele De Bonis; Florian Wagner; Hermann Reichenspurner; Stefan Blankenberg; Alberto Zangrillo; Dirk Westermann
Journal:  Eur J Heart Fail       Date:  2016-10-06       Impact factor: 15.534

5.  Inhaled nitric oxide after left ventricular assist device implantation: a prospective, randomized, double-blind, multicenter, placebo-controlled trial.

Authors:  Evgenij Potapov; Dan Meyer; Madhav Swaminathan; Michael Ramsay; Aly El Banayosy; Christoph Diehl; Bryan Veynovich; Igor D Gregoric; Marian Kukucka; Tom W Gromann; Nandor Marczin; Kanti Chittuluru; James S Baldassarre; Mark J Zucker; Roland Hetzer
Journal:  J Heart Lung Transplant       Date:  2011-04-29       Impact factor: 10.247

6.  Inhaled Nitric Oxide Augments Left Ventricular Assist Device Capacity by Ameliorating Secondary Right Ventricular Failure.

Authors:  Mark A Lovich; Matthew J Pezone; Matthew G Wakim; Ryan J Denton; Mikhail Y Maslov; Michael R Murray; Hisashi Tsukada; Arvind K Agnihotri; Robert F Roscigno; Lucas G Gamero; Richard J Gilbert
Journal:  ASAIO J       Date:  2015 Jul-Aug       Impact factor: 2.872

7.  Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction.

Authors:  E Loh; J S Stamler; J M Hare; J Loscalzo; W S Colucci
Journal:  Circulation       Date:  1994-12       Impact factor: 29.690

8.  Response to inhaled nitric oxide in patients with acute right heart syndrome.

Authors:  S Bhorade; J Christenson; M O'connor; A Lavoie; A Pohlman; J B Hall
Journal:  Am J Respir Crit Care Med       Date:  1999-02       Impact factor: 21.405

Review 9.  The right ventricle: interaction with the pulmonary circulation.

Authors:  Michael R Pinsky
Journal:  Crit Care       Date:  2016-09-10       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.